It was found that the revenue and net income of multiple national vaccine companies, including chongqing zhifei biological products, walvax biotechnology, beijing wantai biological pharmacy enterprise, shenzhen kangtai biological products, and Hualan Vaccine, have all seen a significant decline, with the highest decrease reaching nearly 80%. An analyst specializing in the pharmaceutical industry at a brokerage said, "With the increase in the number of market competitors, the market competition has become more intense. In the background of many vaccine companies lowering prices to compete for market share, it remains to be further observed which companies can maintain their market position." (21st Century Business Herald)